Advanced search
Publication Cover
Future Lipidology Volume 1, 2006 - Issue 6
Journal homepage
118
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Statins in diabetics, beyond cholesterol?

Peter VosholLeiden University Medical Center, Department of Endocrinology & Metabolic Diseases, C4-R, Room 67, PO Box 9600, 2300 RC, Leiden, Netherlands, Tel.: +31 715 263 744; Fax.: +31 715 248 136, E-mail: [email protected]Correspondence[email protected]
,
Louis HavekesTNO-Quality of life & Department of Internal Medicine & Cardiology, LUMC, Biomedical Research Unit, PO Box 2215, 2301 CE Leiden, Leiden, Netherlands, Tel.: +31 715 181 449; Fax.: +31 715 181 904, E-mail: [email protected]Correspondence[email protected]
&
Johannes RomijnDepartment of Endocrinology & Metabolic Diseases, C4-R, PO Box 9600, 2300 RC, Leiden, Netherlands, Tel.: +31 715 263 077; Fax.: +31 715 248 136, E-mail: [email protected]Correspondence[email protected]
Pages 667-671 | Published online: 18 Jan 2017

  • Isley WL, Miles JM, Patterson BW, Harris WS: The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with Type 2 diabetes mellitus. J. Lipid Res. 47(1), 193–200 (2006).
  • Isley WL, Harris WS, Miles JM: The effect of high-dose simvastatin on free fatty acid metabolism in patients with Type 2 diabetes mellitus. Metabolism 55(6), 758–762 (2006).
  • Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 1697(2A), A3–A11 (2006).
  • Ginsberg HN, Zhang YL, Hernandez-Ono A: Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14(Suppl. 1), S41–S49 (2006).
  • Schneider JG, von Eynatten M, Parhofer KG et al.: Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 175(2), 325–331 (2004).
  • Sato A, Watanabe K, Fukuzumi H, Hase K, Ishida F, Kamei T: Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats. Biochem. Pharmacol. 41(8), 1163–1172 (1991).
  • Kobayashi J, Maruyama T, Masuda M, Shinomiya M: Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin. Chim. Acta 314(1–2), 261–264 (2001).
  • Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T: Effects of atorvastatin versus fenofibrate on ApoB-100 and ApoA-I kinetics in mixed hyperlipidemia. J. Lipid Res. 45(1), 174–185 (2004).
  • Lemieux I, Salomon H, Despres JP: Contribution of ApoC-III reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Ann. Med. 35(6), 442–448 (2003).
  • Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452(3), 160–164 (1999).
  • George J: Angiopoietin-like proteins: another player in the metabolic field. J. Hepatol. 44(4), 832–834 (2006).
  • Fajas L, Schoonjans K, Gelman L et al.: Regulation of peroxisome proliferatoractivated receptor- expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol. Cell Biol. 19(8), 5495–5503 (1999).
  • Lu G, Windsor SL, Harris WS: Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitro conversion of very low density lipoproteins to low density lipoproteins. J. Nutr. Biochem. 10(3), 151–158 (1999).
  • Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J. Clin. Invest. 116(7), 1793–801 (2006).
  • Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109(21 Suppl. 1), II8–II26 (2004).
  • ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AF: Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur. J. Clin. Invest. 35(9), 558–564 (2005).
  • Zechner R, Strauss J, Frank S et al.: The role of lipoprotein lipase in adipose tissue development and metabolism. Int. J. Obes. Relat. Metab. Disord. 24(Suppl. 4), S53–S56 (2000).
  • Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ: Apolipoprotein C3 deficiency results in dietinduced obesity and aggravated insulin resistance in mice. Diabetes 54(3), 664–671 (2005).
  • Jong MC, Voshol PJ, Muurling M et al.: Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 50(12), 2779–2785 (2001).
  • Goudriaan JR, Tacken PJ, Dahlmans VE et al.: Protection from obesity in mice lacking the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 21(9), 1488–1493 (2001).
  • Reddy JK, Rao MS: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290(5), G852–G858 (2006).
  • Levy DR, Pearson TA: Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clin. Cardiol. 28(7), 317–320 (2005).
  • Nambi V, Ballantyne CM: Combination therapy with statins and omega-3 fatty acids. Am. J. Cardiol. 98(4A), I34–I38 (2006).
  • Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega- 3 fatty acids. Am. J. Cardiol. 98(4A), I27–I33 (2006).
  • Pourcet B, Fruchart JC, Staels B, Glineur C: Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. Exp. Opin. Emerg. Drugs 11(3), 379–401 (2006).
  • Semple RK, Chatterjee VK, O’Rahilly S: PPAR- and human metabolic disease. J. Clin. Invest. 116(3), 581–589 (2006).
  • Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR- in energy metabolism and vascular homeostasis. J. Clin. Invest. 116(3), 571–580 (2006).
  • Schaefer EJ, Asztalos BF: Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr. Opin. Lipidol. 17(4), 394–398 (2006).
  • Mabuchi H, Inazu A: Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. Future Lipidol. 1(4), 487–500 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.